Philips Unveils SmartIQ with 50% Lower X-Ray Dose and IntraSight Plus
At EuroPCR 2026, Philips introduced SmartIQ Technology delivering over 50% less X-ray dose for coronary procedures alongside the new IntraSight Plus platform combining diagnostic and treatment planning tools for precision PCIs. Additional launches include DeviceGuide AI-assisted device visualization, VeriSight Pro 3D ICE real-time imaging, and Hemo R2 unified hemodynamic interface.
1. EuroPCR 2026 Demonstration
At EuroPCR 2026 in Paris, Philips highlighted its integrated image-guided therapy portfolio, showcasing how combined imaging, physiology and AI guidance streamline complex PCI and structural heart procedures in a unified workflow.
2. SmartIQ Ultra-Low Dose Technology
Philips’ SmartIQ Technology, launched at EuroPCR, delivers high-quality coronary imaging with over 50% lower X-ray dose compared to standard low-dose settings, supporting safer procedures for patients and staff.
3. New Platforms and AI-Enabled Tools
The new IntraSight Plus platform consolidates diagnostic and treatment planning tools for precise PCI decision-making, while DeviceGuide merges live ultrasound and X-ray imaging for real-time device navigation in structural heart interventions.
4. Advanced Imaging, Hemodynamics, and Training
Philips also introduced VeriSight Pro 3D ICE for intracardiac real-time imaging and Hemo R2, a unified hemodynamic interface, alongside hands-on sessions and symposia on physiology-guided PCI and advanced imaging workflows.